Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David McConkey

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Oncoimmunology|May 10, 2019
Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activationDevin Plote, Woonyoung Choi, Sharada Mokkapati, et al.
Urologic Oncology|December 3, 2014
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute ForumColin P N Dinney, Donna Hansel, David McConkey, et al.
Journal of Extracellular Vesicles|January 31, 2024
Tumour tissue-derived small extracellular vesicles reflect molecular subtypes of bladder cancerLiang Dong, Mingxiao Feng, Morgan D Kuczler, et al.
European Urology Oncology|February 17, 2020
Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression ProfileJean Hoffman-Censits, Woonyoung Choi, Sumanta Pal, et al.
Biorxiv : the Preprint Server for Biology|January 3, 2024
Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonistPeter K Um, Monali Praharaj, Kara A Lombardo, et al.
European Urology|December 6, 2025
Dynamics of Tumor-informed Circulating Tumor DNA and Association with Clinical Responses to Enfortumab and Pembrolizumab in Patients with Locally Advanced or Metastatic Urothelial CarcinomaEvangelia Vlachou, Burles Avner Johnson, Max Kates, et al.
Nature Reviews. Urology|June 16, 2021
100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19Niyati Lobo, Nathan A Brooks, Alexandre R Zlotta, et al.
Ebiomedicine|September 11, 2016
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical UseVipulkumar Dadhania, Miao Zhang, Li Zhang, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Combined Mek inhibition and <i>Pparg</i> activation Eradicates Muscle Invasive Bladder cancer in a Mouse Model of BBN-induced CarcinogenesisTiffany Tate, Sakina A Plumber, Hikmat Al-Ahmadie, et al.
Nature Communications|February 16, 2022
Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancerAlok Kumar Singh, Monali Praharaj, Kara A Lombardo, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Oncoimmunology|May 10, 2019
Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activationDevin Plote, Woonyoung Choi, Sharada Mokkapati, et al.
Urologic Oncology|December 3, 2014
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute ForumColin P N Dinney, Donna Hansel, David McConkey, et al.
Journal of Extracellular Vesicles|January 31, 2024
Tumour tissue-derived small extracellular vesicles reflect molecular subtypes of bladder cancerLiang Dong, Mingxiao Feng, Morgan D Kuczler, et al.
European Urology Oncology|February 17, 2020
Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression ProfileJean Hoffman-Censits, Woonyoung Choi, Sumanta Pal, et al.
Biorxiv : the Preprint Server for Biology|January 3, 2024
Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonistPeter K Um, Monali Praharaj, Kara A Lombardo, et al.
European Urology|December 6, 2025
Dynamics of Tumor-informed Circulating Tumor DNA and Association with Clinical Responses to Enfortumab and Pembrolizumab in Patients with Locally Advanced or Metastatic Urothelial CarcinomaEvangelia Vlachou, Burles Avner Johnson, Max Kates, et al.
Nature Reviews. Urology|June 16, 2021
100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19Niyati Lobo, Nathan A Brooks, Alexandre R Zlotta, et al.
Ebiomedicine|September 11, 2016
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical UseVipulkumar Dadhania, Miao Zhang, Li Zhang, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Combined Mek inhibition and <i>Pparg</i> activation Eradicates Muscle Invasive Bladder cancer in a Mouse Model of BBN-induced CarcinogenesisTiffany Tate, Sakina A Plumber, Hikmat Al-Ahmadie, et al.
Nature Communications|February 16, 2022
Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancerAlok Kumar Singh, Monali Praharaj, Kara A Lombardo, et al.
Pageof 8